NSPR
InspireMD, Inc.
NASDAQ · Healthcare · Medical - Devices · IL
$0.44
−3.34%Sep 21, 2026, 13:00 UTC
InspireMD amended certain Series J and Series K warrants, potentially raising up to $11 million in gross proceeds, with the amendments aligning the warrants' trigger event to the anticipated FDA approval of CGuard Prime 80 cm.
Source:Aug 14, 2026, 23:56 UTC
InspireMD, Inc. reported a Q2 2026 net loss of $0.17 per share, beating the Zacks Consensus Estimate of a $0.20 loss and improving from a $0.26 loss a year earlier.
Jun 16, 2026, 17:49 UTC
InspireMD announced positive 30-day results from the CGUARDIANS II clinical trial for its CGuard Prime 80 cm carotid stent implant in TCAR procedures.
Source:Jun 12, 2026, 20:05 UTC
InspireMD granted 91,161 shares of restricted stock to six new non-executive employees as inducement grants on June 12, 2026.
Source: